CollPlant Biotechnologies (CLGN) Competitors $1.39 -0.01 (-0.59%) Closing price 07/9/2025 03:20 PM EasternExtended Trading$1.43 +0.04 (+2.74%) As of 07:43 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLGN vs. NSPR, SURG, EDAP, HYPR, ICCM, CTCX, MDAI, APT, MLSS, and DXRShould you be buying CollPlant Biotechnologies stock or one of its competitors? The main competitors of CollPlant Biotechnologies include InspireMD (NSPR), SurgePays (SURG), EDAP TMS (EDAP), Hyperfine (HYPR), IceCure Medical (ICCM), Carmell (CTCX), Spectral AI (MDAI), Alpha Pro Tech (APT), Milestone Scientific (MLSS), and Daxor (DXR). These companies are all part of the "medical equipment" industry. CollPlant Biotechnologies vs. Its Competitors InspireMD SurgePays EDAP TMS Hyperfine IceCure Medical Carmell Spectral AI Alpha Pro Tech Milestone Scientific Daxor InspireMD (NYSE:NSPR) and CollPlant Biotechnologies (NASDAQ:CLGN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, analyst recommendations, risk and earnings. Is NSPR or CLGN more profitable? InspireMD has a net margin of -413.96% compared to CollPlant Biotechnologies' net margin of -560.92%. InspireMD's return on equity of -69.42% beat CollPlant Biotechnologies' return on equity.Company Net Margins Return on Equity Return on Assets InspireMD-413.96% -69.42% -57.68% CollPlant Biotechnologies -560.92%-87.33%-65.31% Which has higher valuation and earnings, NSPR or CLGN? CollPlant Biotechnologies has lower revenue, but higher earnings than InspireMD. InspireMD is trading at a lower price-to-earnings ratio than CollPlant Biotechnologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInspireMD$7.03M10.59-$19.92M-$0.79-3.08CollPlant Biotechnologies$510K34.71-$16.61M-$1.22-1.14 Does the media prefer NSPR or CLGN? In the previous week, InspireMD had 5 more articles in the media than CollPlant Biotechnologies. MarketBeat recorded 5 mentions for InspireMD and 0 mentions for CollPlant Biotechnologies. InspireMD's average media sentiment score of 0.58 beat CollPlant Biotechnologies' score of 0.00 indicating that InspireMD is being referred to more favorably in the media. Company Overall Sentiment InspireMD Positive CollPlant Biotechnologies Neutral Which has more risk and volatility, NSPR or CLGN? InspireMD has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500. Comparatively, CollPlant Biotechnologies has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500. Do analysts prefer NSPR or CLGN? InspireMD presently has a consensus price target of $4.50, indicating a potential upside of 85.19%. CollPlant Biotechnologies has a consensus price target of $11.50, indicating a potential upside of 726.27%. Given CollPlant Biotechnologies' stronger consensus rating and higher probable upside, analysts clearly believe CollPlant Biotechnologies is more favorable than InspireMD.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InspireMD 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00CollPlant Biotechnologies 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Do insiders and institutionals believe in NSPR or CLGN? 44.8% of InspireMD shares are owned by institutional investors. Comparatively, 21.7% of CollPlant Biotechnologies shares are owned by institutional investors. 34.1% of InspireMD shares are owned by insiders. Comparatively, 9.6% of CollPlant Biotechnologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. SummaryInspireMD beats CollPlant Biotechnologies on 9 of the 16 factors compared between the two stocks. Get CollPlant Biotechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for CLGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CLGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLGN vs. The Competition Export to ExcelMetricCollPlant BiotechnologiesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$17.80M$2.90B$5.51B$8.95BDividend YieldN/A2.44%5.25%4.04%P/E Ratio-1.1421.0128.0220.16Price / Sales34.71257.28410.25174.36Price / CashN/A41.8337.0657.97Price / Book1.187.868.145.62Net Income-$16.61M-$54.96M$3.16B$248.50M7 Day Performance0.57%5.27%3.13%4.49%1 Month Performance-21.81%3.78%3.47%7.03%1 Year Performance-72.71%5.85%34.20%21.07% CollPlant Biotechnologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLGNCollPlant Biotechnologies2.6813 of 5 stars$1.39-0.6%$11.50+726.3%-73.7%$17.80M$510K-1.1470Upcoming EarningsNSPRInspireMD3.328 of 5 stars$2.27-0.9%$4.50+98.2%+1.0%$69.54M$7.03M-3.0350News CoverageGap UpHigh Trading VolumeSURGSurgePays3.1976 of 5 stars$3.11-2.2%$9.00+189.4%+17.1%$64.91M$60.88M-1.1140News CoverageEDAPEDAP TMS2.3911 of 5 stars$1.65-1.2%$8.50+415.2%-69.7%$62.44M$69.18M-2.66230HYPRHyperfine1.8789 of 5 stars$0.72-3.0%$1.06+47.3%-20.2%$57.72M$12.89M-1.33190Gap UpICCMIceCure Medical2.1214 of 5 stars$1.00-1.4%$2.50+151.1%+43.2%$56.06M$3.29M-3.5660Gap DownCTCXCarmellN/A$2.59-0.8%N/A+38.2%$54.14M$32.84K0.0014MDAISpectral AI3.1656 of 5 stars$2.48+17.0%$4.75+91.5%+59.4%$53.67M$29.58M-4.5983Gap UpHigh Trading VolumeAPTAlpha Pro Tech1.0373 of 5 stars$4.69-0.8%N/A-11.3%$50.95M$58.18M12.68120MLSSMilestone Scientific2.8783 of 5 stars$0.64-12.4%$1.25+96.4%-3.5%$49.95M$8.61M-9.0930Negative NewsGap UpDXRDaxorN/A$9.79+7.0%$25.00+155.4%+8.1%$44.26MN/A0.0037Gap Up Related Companies and Tools Related Companies InspireMD Competitors SurgePays Competitors EDAP TMS Competitors Hyperfine Competitors IceCure Medical Competitors Carmell Competitors Spectral AI Competitors Alpha Pro Tech Competitors Milestone Scientific Competitors Daxor Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CLGN) was last updated on 7/10/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | SponsoredHow a Kansas farm boy gained 1,285% in two daysA former farm kid placed a simple trade… and cashed out a 1,285% gain two days later. It wasn’t crypto or a...TradeSmith | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CollPlant Biotechnologies Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share CollPlant Biotechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.